Virios Therapeutics Inc
VIRI
Get informed when a big investor buys or sells
+ FollowMarket Cap$206.5K
Close$
$0.18
14% upside
Current Fair Value
14% upsideUndervalued by 14% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $206,502.00 |
|---|---|
| Enterprise Value | $-12,866,834.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.13 |
| Beta | 1.58 |
| Outstanding Shares | 33,544,748 |
Return
| Return on Equity | 15059.05% |
|---|---|
| Return on Assets | 12752.22% |
| Return on Invested Capital | -21239.62% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 0.08 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
November 7, 2025
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Dogwood Therapeutics, Inc.
12 employees
CEO: Gregory Duncan Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate...